AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03096782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV
Study NCT03096782 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo total body irradiation
Study NCT03096782 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo cord blood transplant
Study NCT03662750 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brain Imaging
Description: The study involves an initial screening visit and 2 study imaging visits at days 15 and 90 after the stroke episode.Patients will undergo:~1. Two 90-minute brain imaging sessions using Positron Emission Tomography (PET) (involves injection of safe radiotracers which attach to brain immune cell markers TSPOs and light up the inflamed areas in the brain),~2. Two 45-90 minute Magnetic Resonance Imaging (MRI) scanning sessions (include administration of safe chemical contrast agent Gadolinium),~3. Physical and neurological examinations (vital signs, assessments of mobility and cognitive functioning),~4. Blood testing (routine measurements, blood inflammation markers, and genetic testing for TSPO marker).~Venous cannula will be inserted into the forearm for the duration of the scans.
Study NCT00612313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Participants will take 10 to 40 mg per day of fluoxetine for 30 weeks.
Study NCT00612313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Participants will take 10 to 40 mg per day of fluoxetine for 30 weeks.
Study NCT00612313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relapse prevention cognitive behavioral therapy (CBT)
Description: After the first 6 weeks of treatment with fluoxetine, some participants will be assigned to additionally receive relapse prevention CBT for the remaining 24 weeks of treatment. These participants will attend 10 to 12 CBT sessions, during which they will learn specific skills to reduce and prevent the occurrence of residual depressive symptoms.
Study NCT02927691 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EMST
Study NCT02927691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMST
Study NCT02927691 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: smTAP
Study NCT02927691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smTAP
Study NCT02497768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing of nuts
Description: The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (pistachios or Brazils) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
Study NCT03202316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT03202316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO
Study NCT03202316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Given IV
Study NCT03202316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03202316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT05059015 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CERVICAL HPV
Description: A screening test with an HPV test is performed by a health professional plus cytology taking, if it reports positive, colposcopy and biopsy are taken, those with a CIN2 + report are directed to receive treatment.
Study NCT05059015 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SELF SAMPLING HPV
Description: A screening test is performed with an HPV test by self-testing, if it reports positive, women will receive ablative treatment according to eligibility criteria. If they do not meet the criteria for ablation, they will be referred for excisional treatment.
Study NCT03843788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Starting 8 hours after cesarean section, the TENS unit will be applied with charges above and below the incision. The device will be set to high frequency (>75 Hz) for pain relief. Intensity of stimulation will be set to patient threshold using the forearm as a guide. Stimulation will be turned on titrated to the level which is felt but not painful for the patient. It will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy.
Study NCT03823651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval training
Description: Patients will be asked to complete up to 3 x 30-minute structured high intensity interval training aerobic exercise sessions/week. For the first session, patients will come to the Duke Center for Living for in person evaluation and training. After the initial training session in person, a subsequent training session will take place at the patient's home via iPad/iPhone videoconference using a device provided to the patient to provide additional support and the opportunity to answer questions. Subsequent sessions will be done independently by patients, but study staff will be available via iPad/iPhone if questions arise.
Study NCT03823651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychiatric consult
Description: Subjects who score below threshold on the PHQ2/PHQ9, PC-PTSD/PCL-5, PROMIS-Depression and/or PROMIS-Anxiety assessments will be referred to a psychiatrist for follow up.
Study NCT03823651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition/diet evaluation
Description: PG-SGA, ASA24, food group tracking Assessments and Vit D, Vit A, albumin, prealbumin, lipids, A1c levels will be used to provide weekly feedback for one month
Study NCT03823651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral to Social Worker
Description: Subjects who score below threshold on the PROMIS-Emotional Support and/or PROMIS-Social Isolation assessments will be referred to a social worker for follow up
Study NCT01464918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD) using device, MASTER
Description: Performing endoscopic submucosal dissection (ESD)of the gastric/colon cancer using the device, MASTER
Study NCT02586701 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prehabilitation Plus
Description: Supervised exercise program and home-based exercise program.
Study NCT00687505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-1039
Description: Intravenous weekly administration
Study NCT02839434 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample
Description: This blood sample does not require specific puncture because it is made on the occasion of a sample justified by the patient monitoring.
Study NCT00620230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NVP-VAK694
Study NCT01312116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT
Description: Internet-delivered cognitive behavior therapy, 8 weeks
Study NCT01312116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iPDT
Description: Internet-delivered psychodynamic therapy, 8 weeks
Study NCT01326780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.2% JNJ 10229570-AAA
Description: 1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks
Study NCT01326780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.4% JNJ 10229570-AAA
Description: 2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks
Study NCT01326780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.6% JNJ 10229570-AAA
Description: 3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks
Study NCT01326780 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle control
Description: Color matched cream vehicle, applied once daily to the face for 12 weeks
Study NCT01176825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive-behavior therapy (CBT)
Description: 14 sessions of individual cognitive-behavior therapy. Sessions last 50-60 minutes and are held weekly. 2 optional monthly booster sessions may also be held after the end of treatment.
Study NCT01668095 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04292158 — intervention group
Intervention type: DEVICE
Intervention: SomnoTouch
Description: The patient will be equipped with the SomnoTouch device. This device is able to record and estimate the following data:~ECG data PPG data Heart rate Respiration rate Blood pressure (mmHg) Oxygen saturation (%).~All patient will be stored for further analysis.
Study NCT04292158 — intervention group
Intervention type: DEVICE
Intervention: MOX
Description: The patient will be equipped with the MOX device. This device is able to record and estimate the following data:~Accelerometers data Activity Body posture~All patient will be stored for further analysis.
Study NCT03992105 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: prospective cohort
Description: topics included openly in the Respite Site, made up of the first 50 subjects followed prospectively
Study NCT01455883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650 60 mcg/day
Description: exenatide in DUROS
Study NCT01455883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: oral glimepiride does-escalated,if tolerated, to 8 mg/day
Study NCT03508089 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ocular fundus on patient with Multiple Sclerosis
Description: Ocular fundus on patient with Multiple Sclerosis
Study NCT03508089 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ocular Fundus on voluntary person
Description: Ocular Fundus on voluntary person
Study NCT01023126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Psychotherapy
Description: Group psychotherapy once a week, under a psychiatrist supervision
Study NCT00600821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab is available as 100 and 400 mg preservative-free, single use vials- The starting dose is 15 mg/kg, iv infusion, every 3 weeks.
Study NCT00600821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg\*min/ml, iv infusion, every 3 weeks.
Study NCT00600821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
Study NCT00600821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736 (axitinib)
Description: AG-013736 (axitinib) is available as 1mg, and 5 mg film-coated tablets for oral administration- The starting dose is 5 mg BID-
Study NCT00600821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg\*min/ml, iv infusion, every 3 weeks.
Study NCT00600821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
Study NCT03290508 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Prolaris Testing
Description: Recently diagnosed treatment-naïve patients with early stage localized prostate cancer who undergo Prolaris testing
Study NCT04140669 — intervention group
Intervention type: DEVICE
Intervention: Automated Myocardial Performance Index (MPI)
Description: Automated Myocardial Performance Index will be performed using Samsung HERA W10 prior too fetal surgical interventions, during surgery, and following surgery.
Study NCT01124890 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: early percutaneous coronary intervention
Study NCT01124890 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: late percutaneous coronary intervention
Study NCT04307758 — intervention group
Intervention type: OTHER
Intervention: Muscle Strength Assesment-Make Test
Description: For the make test, the examiner applies resistance in a fixed position and the person being tested exerts a maximum effort against the dynamometer and examiner. The examiner is only required to sustain an isometric contraction and read the highest value on an Hand Held Dynamometer.
Study NCT04307758 — intervention group
Intervention type: OTHER
Intervention: Muscle Strength Assesment-Break Test
Description: For the break test, the examiner applies resistance sufficient to overcome the maximum effort of the person being tested and cause the subject's joint to move in the opposite direction, which results in an eccentric contraction. During this test the limb must move at a constant velocity while the person being tested is asked to achieve a maximum contraction. In addition, the examiner must read the force output reading at the exact time the subject's limb begins to move from the Hand Held Dynamometer.
Study NCT04132349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate 5 mg
Description: Ulipristal acetate (from Cenexi manufacturer, France) at daily dose of 5mg in 3 consecutive months course
Study NCT02517580 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (MK7)
Study NCT01625052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement and use of Baska mask
Description: use of Baska mask as component of standard general anaesthetic
Study NCT03062488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV acetaminophen
Description: multi-modal analgesia with IV acetaminophen
Study NCT03062488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: single modal analgesia
Study NCT03388073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Berry extract I
Description: Seabuckthorn berry proanthocyanidin extract 250 mg single dose
Study NCT03891732 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI prostate
Description: plain biparametric MRI prostate
Study NCT04166877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate in Parenteral Dosage Form
Description: IV bolus followed by continuous infusion for 24 hours
Study NCT04166877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline placebo
Description: IV bolus followed by continuous infusion for 24 hours
Study NCT04305184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0598
Description: ASP0598 Otic solution was administered onto the Tympanic Membrane (TM) through the external auditory canal via syringe.
Study NCT04305184 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to ASP0598 Otic solution was administered onto the TM through the external auditory canal via syringe.
Study NCT03388073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Berry Extract II
Description: Seabuckthorn berry proanthocyanidin extract 500 mg single dose
Study NCT03388073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Berry extract blend
Description: Seabuckthorn berry blend with other berry-based antioxidants
Study NCT03388073 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00030797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan 70 mg/m2
Description: Irinotecan i.v. 70 mg/m2, day 1, 8, 15, 22, 29
Study NCT00030797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan 240 mg/m2
Description: Irinotecan i.v. 240 mg/m2 day 1 and day 22
Study NCT03882619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calligraphy
Description: Participants will (1) detect the emotion him or herself; (2) do the calligraphy activity by writing positive terms (e.g., peace, life); (3) detect emotion again; (4) share the experience with group members.
Study NCT01014494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaprev
Description: Class III Medical Device
Study NCT01696630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Study NCT01696630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Study NCT02205619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Flow Master Piezon®, EMS SA, Nyon, Swiss
Description: comparison of different instruments on root cementum: Instrumentations with US devices ( Air Flow Master Piezon®, EMS SA, Nyon, Swiss) were performed with medium power settings and with the use of water cooling (as instructed by the manufacturer). One approximal root surface (distal and mesial) of each tooth was randomly subjected to debridement and the other approximal surface was used as control. All the instrumentations of teeth were performed by a single operator. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia.
Study NCT02205619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gracey curettes, American Eagle, Missoula, MT, USA
Description: comparison of different instruments on root cementum Hand instruments (Gracey curettes 5/6, 11/12, 13/14 American Eagle, Missoula, MT, USA) were used for subgingival root instrumentation. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia.
Study NCT02205619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air-flow® Powder Perio, EMS SA, Nyon, Swiss
Description: comparison of different instruments on root cementum: Instrumentations with air polishing (Air-flow® Powder Perio, EMS SA, Nyon, Swiss) were performed with a special nozzle and medium power settings and with the use of water cooling (as instructed by the manufacturer). One approximal root surface (distal and mesial) of each tooth was randomly subjected to debridement and the other approximal surface was used as control. All the measurements and instrumentations of teeth were performed by a single operator. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia
Study NCT03015077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: oral glutamine
Description: L-Glutamine and maltodextrin are both nutritional supplements. In the glutamine arm: 10 g L-Glutamine and 5 g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
Study NCT03015077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: in the placebo arm: 15 g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
Study NCT03015077 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: All patients undergo radiotherapy. 5 days a week. All patients had a dental evaluation for good oral hygiene prior to computed tomography simulation for radiotherapy. Post-operative patients received planned course of adjuvant treatment of 60 to 66 Gy in 2-Gy fractions to the surgical bed. The course of radiation was initiated no more than 6 weeks after resection. Patients without operation received definitive treatment to 70 Gy in 2-Gy fractions.
Study NCT03015077 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: All patients undergo radiotherapy. 5 days a week. All patients had a dental evaluation for good oral hygiene prior to computed tomography simulation for radiotherapy. Post-operative patients received planned course of adjuvant treatment of 60 to 66 Gy in 2-Gy fractions to the surgical bed. The course of radiation was initiated no more than 6 weeks after resection. Patients without operation received definitive treatment to 70 Gy in 2-Gy fractions.
Study NCT04534127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
Study NCT04400253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAATH Intervention
Description: SAATH intervention is a physical activity intervention for South Asian mothers and daughters with group exercise classes and discussion groups.
Study NCT03548610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nanofat-seeded biological scaffold on surgical defect
Description: Nanofat-seeded biological scaffold in healing larger surgical defects (>1.5cm) involving the lower limbs
Study NCT01706952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cocaine
Description: Pledgets soaked in 4% cocaine hydrochloride solution were placed intranasally (one side).